Did you mean 3.2.0 001 5?
Displaying drugs 6901 - 6925 of 11214 in total
alpha-D-glucose-1-phosphate
Experimental
Matched Synonyms: … glucose-1-phosphate …
Matched Name: … alpha-D-glucose-1-phosphate …
Matched Iupac: … {[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phosphonic acid …
Matched Salts name: … alpha-Glucose-1-phosphate disodium tetrahydrate …
Matched Products: … Glucose-1-phosphat "Fresenius" 1 molar - Infusionszusatz - Ampullen …
Matched Name: … alpha-D-glucose-1-phosphate …
Matched Iupac: … {[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phosphonic acid …
Matched Salts name: … alpha-Glucose-1-phosphate disodium tetrahydrate …
Matched Products: … Glucose-1-phosphat "Fresenius" 1 molar - Infusionszusatz - Ampullen …
N4-Hydroxycytidine
N4-Hydroxyctidine, or EIDD-1931, is a ribonucleoside analog which induces mutations in RNA virions.[A193008,A193011] N4-hydroxycytidine was first described in the literature in 1980 as a potent mutagen of bacteria and phage. It has shown antiviral activity against Venezuelan equine encephalitis virus, and the human coronavirus HCoV-NL63 in vitro. N4-hydroxycytodine has been...
Experimental
Matched Iupac: … 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-(hydroxyamino)-1,2-dihydropyrimidin-2- …
Matched Description: … [A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’ ... [A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Description: … [A193014] It is orally bioavailable in mice and distributes into tissue before becoming the active 5’ ... [A193017] N4-hydroxycytodine has been shown to inhibit SARS-CoV-2 as well as other human and bat coronaviruses …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Borneol
Experimental
Matched Synonyms: … endo-2-bornanol ... endo-2-camphanol ... endo-2-hydroxycamphane …
Matched Iupac: … 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol …
Matched Iupac: … 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol …
Cinalukast
Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
Experimental
Matched Synonyms: … 3'-((E)-2-(4-cyclobutyl-2-thiazolyl)vinyl)-2,2-diethylsuccinanilic acid …
Matched Iupac: … 3-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}carbamoyl)-2,2-diethylpropanoic acid …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Iupac: … 3-({3-[(E)-2-(4-cyclobutyl-1,3-thiazol-2-yl)ethenyl]phenyl}carbamoyl)-2,2-diethylpropanoic acid …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Peptide YY (3-36)
Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Synonyms: … PYY 3-36 ... PYY(3-36) ... Pyy (3-36) peptide …
Matched Name: … Peptide YY (3-36) …
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …
Matched Name: … Peptide YY (3-36) …
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …
Ralimetinib
Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.
Investigational
Matched Iupac: … 5-[2-tert-butyl-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin- ... 2-amine …
Matched Salts cas: … 862507-23-1 …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Salts cas: … 862507-23-1 …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
AGS-499
Investigational
VLTS-589
VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational
Matched Description: … VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 …
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Iupac: … (1r,4r)-4-({2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl] ... phenyl}amino)cyclohexyl 2-aminoacetate …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Heterocyclic Compounds, 2-Ring …
KRN-5500
KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Investigational
Matched Iupac: … 3-yl]carbamoyl}methyl)tetradeca-2,4-dienamide ... (2E,4E)-N-({[(2R,3R,4R,5R,6S)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-[(9H-purin-6-yl)amino]oxan- …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 2-Ring …
V590
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
AZD-5069
Investigational
Matched Iupac: … -1-sulfonamide ... N-(2-{[(2,3-difluorophenyl)methyl]sulfanyl}-6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}pyrimidin-4-yl)azetidine …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring …
TERT-572
Investigational
KITE-585
KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Investigational
ABBV-514
ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
Investigational
Matched Description: … NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 …
AZD-5672
Azd5672 has been used in trials studying the basic science and treatment of Pharmacokinetics, Renal Impairment, and Rheumatoid Arthritis.
Investigational
Matched Iupac: … N-{1-[(3R)-3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl]piperidin-4-yl}-N-ethyl-2-(4-methanesulfonylphenyl …
AZD-5423
AZD5423 has been used in trials studying the basic science and treatment of Asthma, Bioavailability and AUC, and Chronic Obstructive Pulmonary Disease (COPD).
Investigational
Matched Iupac: … 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)propan-2-yl …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Heterocyclic Compounds, 2-Ring …
Matched Categories: … Heterocyclic Compounds, 1-Ring ... Heterocyclic Compounds, 2-Ring …
AZD-5991
AZD-5991 is under investigation in clinical trial NCT03218683 (Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.).
Investigational
Matched Iupac: … 5,6,12,13,22-pentaazaheptacyclo[27.7.1.1^{4,7}.0^{11,15}.0^{16,21}.0^{20,24}.0^{30,35}]octatriaconta-1( …
NDI-5001
Investigational
Matched Synonyms: … 1-(12-(1 carboxycyclopropyl)dodecyl)cyclopropane-1-carboxylic acid …
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
BHV-5000
BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is lanicemine.
Investigational
Displaying drugs 6901 - 6925 of 11214 in total